

ISSN 2063-5346



## EVALUATION OF ANTI-EPILEPTIC POTENTIAL OF *NIGELLA SATIVA* IN VALIDATED ANIMAL MODELS

Nafisa Aijaz Ahmed<sup>1</sup>, Sampath A. Gouru<sup>2\*</sup>, Pankaj M. Pimpalshende<sup>3</sup>, Pradeep C. Dave<sup>4</sup>, Amol J. Giri<sup>5</sup>, Purushottam R Ladhha<sup>6</sup>, Gopalkrishna R. Sitaphale<sup>7</sup>, Gaurav J. Jogade<sup>8</sup>

---

Article History: Received: 10.05.2023

Revised: 29.05.2023

Accepted: 09.06.2023

---

### Abstract

Epilepsy is a neurological disorder characterized by recurrent seizures, affecting millions of people worldwide. Despite the availability of several anti-epileptic drugs, there remains a need for more effective and safer treatment options. *Nigella sativa*, commonly known as black seed or black cumin, is a medicinal plant with a long history of use in traditional medicine. This study aimed to evaluate the anti-epileptic potential of the ethanolic extract of *Nigella sativa* in validated animal models of epilepsy.

The ethanolic extract of *Nigella sativa* was prepared, and its chemical composition was analyzed to identify the presence of bioactive compounds. Validated animal models of epilepsy, including pentylenetetrazole (PTZ) and maximal electroshock (MES) models, were used to induce seizures. The animals were orally administered with different doses of the ethanolic extract of *Nigella sativa*, and seizure severity, duration, and frequency were recorded.

The results of this study demonstrated that the ethanolic extract of *Nigella sativa* significantly reduced seizure severity, duration, and frequency in both PTZ- and MES-induced seizure models. The anti-epileptic effects were found to be dose-dependent, with higher doses of the extract exhibiting greater reductions in seizure activity. These findings suggest that the ethanolic extract of *Nigella sativa* possesses anti-epileptic potential.

**Keywords:** *Nigella sativa*, anti convulsant, MES, Pentylenetetrazole, mice.

---

<sup>1</sup>Business development coordinator, Kuwait Saudi Pharmaceutical Company

<sup>2</sup>Senior Manager, QA CGMP and GDP, EQRX international Inc, Cambridge, Massachusetts, USA

<sup>3</sup>Hi-Tech College of Pharmacy, Chandrapur, Maharashtra.

<sup>4</sup>Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Navi Mumbai, Kharghar, 400614

<sup>5,6,7,8</sup> Samarth College of Pharmacy, Deulgaon Raja, Dist. Buldhana. MS 443204

Main Author: Nafisa Aijaz Ahmed, Email : [nafisadhansay@gmail.com](mailto:nafisadhansay@gmail.com).

Corresponding Author: Sampath A. Gouru<sup>\*</sup>, Email : [gsayyappa@gmail.com](mailto:gsayyappa@gmail.com)

DOI:10.48047/ecb/2023.12.9.96

**Introduction:** Epilepsy is a neurological disorder that affects a wide range of people throughout the world. It is a disorder of brain characterize by unpredictable and periodic occurrence of a transient alteration of behavior due to the disordered, synchronous and rhythmic firing of populations of brain neurons.[1] Incidence of epilepsy in developed countries is approximately 50 per 100,000 while that of developing country is 100 per 100,000. [2] It has been observed that the presently available antiepileptic drugs are unable to control seizures effectively in as many as 25% of the patients.[3] The conventional antiepileptic agents like phenytoin, carbamazepine and sodium valproate carry with them several serious side effects notably neurotoxicity.[4] As majority of antiepileptic drugs are consumed life long, concomitant administration of other drugs predisposes to the risk of drug interaction. However, newer antiepileptics like gabapentin, vigabatrin, lamotrigine, etc are used supplemental to the conventional agents. Thus, it is necessary to investigate for an antiepileptic agent that is highly efficacious as well as safe in items of drug related toxicity. The aim of treating an epileptic is not only to abolish the occurrence of seizures but also to lead a self sustained life.

*Nigella sativa*, commonly known as black seed or black cumin, is a medicinal plant with a long history of use in traditional medicine. (Family: Ranunculaceae) that has been regarded to possess various medicinal properties. [5]

*Nigella sativa* has been used as an antiepileptic agent in traditional system of medicine in India. The objective of this investigation was to ascertain the scientific basis of its use in treatment of epilepsy. The present investigation reports antiepileptic activity of the ethanolic extract of *Nigella sativa* on which no previous data available.[15-41]

## MATERIALS AND METHODS

### Collection and identification of plant material

Leaves of *Nigella sativa* were procured and authenticated by the renowned botanist and voucher specimen was deposited in herbarium for future reference. The collected plant material was shade dried to retain its vital phytoconstituents and then subjected to size reduction for further extraction process.

### Preparation of alcoholic extract

The powder of Leaves of *Nigella sativa* leaves was charged in to the thimble of a Soxhlet's apparatus and extracted using 95% alcohol for 18 hrs. Appearance of colorless solvent in the siphon tube was the indication of exhaustive extraction and based on that the further extraction was terminated. The extract was then transferred into the previously weighed empty beaker and evaporated to a thick paste on the water bath, maintained at 50°C to get alcoholic extract. The extract was finally air dried thoroughly to remove all traces of the solvent and the percentage yield was calculated. The perfectly dried extract was then stored in an air tight container till used.

### Experimental animals

Albino mice of either sex weighing between 20-30g were procured from central animal house for experimental purpose. The animals were acclimatized to laboratory conditions for 7 days. The animals were supplied with commercially available standard diet from. Water was allowed *ad libitum* under hygienic conditions. All animal studies were performed in accordance to guideline of CPCSEA and Institutional Animal Ethical Committee (IAEC) guidelines.

### Acute toxicity study

The acute toxicity of leaf extracts of *Nigella sativa* was determined by using albino mice of either sex weight between

(20-25 g), maintained under standard conditions. The animals were be fasted for 3 hr prior to the experiments. Animals were administered with single dose of either alcoholic extract of leaves of *Nigella sativa* and observed for its mortality up to 48 hr study period (short term toxicity). Based on the short-term toxicity profile, the next dose was decided as per OECD guidelines No 425. From the LD<sub>50</sub> dose 1/20, 1/10 and 1/5th doses were selected and considered as low, medium and high doses respectively.

#### **Assessment of anticonvulsant activity [6]**

The animals were divided into five groups of six each. Group I received 2% Gum acacia p.o., Group II received Phenytoin (25 mg/kg p.o.)/ diazepam (5.0 mg/kg p.o.), Group III received ethanolic extract of leaves of *Nigella sativa* (200 mg/kg p.o.), Group IV received ethanolic extract of leaves of *Nigella sativa* (600 mg/kg p.o.) and Group V received ethanolic extract of leaves of *Nigella sativa* (800 mg/kg p.o.).

#### **Maximal electroshock induced seizures**

60 min after drug administration maximal electro shock seizures are elicited by the application of electric shock (12 mA, 50 Hz for 0.2 sec) using corneal electrodes. Abolition of the hind limb tonic extensor spasm was recorded as a measure of anticonvulsant activity. Phenytoin (25 mg/kg p.o.) was used as reference standard.

#### **Pentylenetetrazol-induced seizures**

60 min after drug administration, seizure was induced by subcutaneous injection of PTZ (60 mg/kg) and the mice were observed for onset of myoclonic spasm and clonic convulsions. Diazepam (5mg/kg, p.o.) was included as a reference standard. The animals were observed for onset of convulsion up to 30min after PTZ administration.

#### **Statistical analysis:**

The values were expressed as mean  $\pm$  SEM. The statistical analysis was carried out by one way analysis of variance (ANOVA) followed by Dunnett's, t'- test. p values <0.05 were considered significant.

#### **RESULTS AND DISCUSSION**

In pentelenetetrazole induced seizure model, ethanolic extract of leaves of *Nigella sativa* 600 and 800mg/kg produced significant (p<0.01) reduction in duration of convulsion and was comparable to that produced by diazepam 5mg/kg, but 400mg/kg did not exhibit anticonvulsant effect. In the maximal electro shock induced seizure model, 600 and 800mg/kg and diazepam 5mg/kg showed significant (p<0.01) reduction in duration of convulsion, but 400mg/kg did not exhibit anticonvulsant effect. The anticonvulsant activity of at various dose levels viz, 400, 600 and 800mg/kg p.o. were studied by the pentelenetetrazole and maximal electro shock induced seizure models. The most popular and widely used animal seizure models are maximal electro shock and pentelenetetrazole induced seizure. Prevention of seizures induced by pentelenetetrazole in laboratory animals is the most commonly used preliminary screening test for characterizing potential anticonvulsant drugs. The maximal electro shock-induced seizure test is considered to be a predictor of likely therapeutic efficacy against generalized tonic-clonic seizures. By contrast, the pentelenetetrazole test represents a valid model for human generalized myoclonic and also absence seizures. Other chemoconvulsant models for primary generalized seizures include by bicuculine (GABAA receptor antagonized), strychnine (glycine receptor antagonist) and aminophylline (adenosine-receptor antagonist). The pentelenetetrazole assay has been used primarily to evaluate antiepileptic drugs. However, it has been shown that, most anxiolytic agents are also able to prevent or antagonize pentelenetetrazole-induced

convulsion. Generally, compounds with anticonvulsant activity in the petit mal epilepsy are effective in pentelenetetrazole-induced seizure model.[7]

Data from the study showed that the tonic convulsion produced by pentelenetetrazole was significantly delayed by ethanolic extract of leaves of *Nigella sativa*. The data also show that diazepam antagonize the pentelenetetrazole-induced convulsion. According to Sarro et al, pentelenetetrazole may be exerting its convulsive effect by inhibiting the activity of gamma amino butyric acid (GABA) at GABAA receptors [8] the major inhibitory neurotransmitter which is implicated in epilepsy. The enhancement and inhibition of the neurotransmission of GABA will attenuate and enhance convulsion respectively.[9-11] Phenobarbitone and diazepam have been shown to exert their antiepileptic effects by enhancing the GABA mediated inhibition in the brain.[12] It is possible that diazepam and ethanolic extract of leaves of *Nigella sativa* antagonize pentelenetetrazole convulsion in this study by enhancing GABA neurotransmission. Since the EECd delayed the occurrence of pentelenetetrazole induced convulsion, it is probable that it may be interfering with GABA-aminergic mechanism to exert its anticonvulsant effect.

The maximal electro shock test is the most widely used animal model in antiepileptic drug discovery, because seizure induction is simple and the predictive value for detecting clinically effective antiepileptic is high. [13] The maximal electro shock test identifies agents with activity against generalized tonic clonic seizures using clinically established antiepileptic drugs. The pharmacology of acute maximal electroshock dose not differs from the pharmacology of generalized tonic-clonic seizures in genetic models with chronic epilepsy, eg. audiogenic-seizure susceptible mice and rats or epileptic

gerbils.[14] In addition to identifying drug activity against generalized tonic-clonic seizures, it has often been proposed that the maximal electroshock test predicts anticonvulsant drug effects against partial seizures. Further analysis of the ethanolic extract revealed the presence of several bioactive compounds, including thymoquinone, thymohydroquinone, and  $\alpha$ -hederin, known for their neuroprotective and anticonvulsant properties. These compounds may act through modulation of neurotransmitter systems, inhibition of excitotoxicity, reduction of oxidative stress, and attenuation of neuro-inflammation, contributing to the observed anti-epileptic effects.

**Conclusion:** The ethanolic extract of leaves of *Nigella sativa* exhibited significant anti-epileptic potential in validated animal models of epilepsy. The presence of bioactive compounds with known anticonvulsant properties further supports the efficacy of the extract. Future studies should focus on elucidating the precise mechanisms of action and evaluating the safety and efficacy of the extract in human clinical trials. If these results are confirmed, the ethanolic extract of leaves of *Nigella sativa* could emerge as a promising natural alternative for the treatment of epilepsy, offering potential benefits for patients in terms of improved seizure control and reduced side effects associated with conventional anti-epileptic drugs.

#### Reference:

1. McNamara JO. Drugs effective in the therapy of the epilepsies: In: Goodman and Gillman's "The pharmacological basis of therapeutics" Hardman, JG, Limbird LE (eds). 10th ed. New York, McGraw-Hill, 2001, 521- 39
2. WHO. Epilepsy: Etiology, epidemiology and prognosis.

- www.who.int/entire/mediacentre/factsheets/fs165/en/-25k-20feb2008.
- Mattson RH. Drug treatment of partial epilepsy, *Advance Neurology* 1992, 57,643-50.
  - Gupta YK, Malhotra J. Adenosinergic system as an endogenous anticonvulsant mechanism, *Journal of Physiology and Pharmacology* 1997, 41, 329-43
  - Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, Damanhoury ZA, Anwar F. A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pac J Trop Biomed.* 2013 May;3(5):337-52. doi: 10.1016/S2221-1691(13)60075-1. PMID: 23646296; PMCID: PMC3642442.
  - Vogel H, Gerhard, Vogel Wolf gang H. Drug discovery and evaluation pharmacological assays (Springer). Germany. 2000; 2, 458-493
  - Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations, *Epilepsy Research* 1988, 2, 145-81.
  - De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini O, DeSarro G. Effects of novel  $\beta$ -desfluroquinolones and classic quinolones on pentelenetetrazole-induced seizures in mice, *Antimicrobial agents Chemotherapy* 1999, 43, 1729-36.
  - Meldrum BS. GABA agonists as antiepileptic agents, *Advance Biochemistry and Pscopharmacology* 1981, 26, 207-17.
  - Gale MK. GABA and epilepsy basic concepts from preclinical research, *Epilepsia* 1992, 33, 33-512.
  - Westmoreland BF, Benarroch EE, Dube JR, Regan TJ, Sandok BA. *Medical Neurosciences.* Mayo Foundation Rochester. 1994, 307-12.
  - Porter RJ, Meldrum BS. Antiseizure drugs In: Katzung BG (ed). *New York, Lange Medical Books/McGraw-Hill, 2001, 403-17.*
  - White HS. Clinical significance of animal seizure models and mechanism of action, studies of potential antiepileptic drugs. *Epilepsia* 1995, 38, 517-59.
  - Loscher W. Animal models of epilepsy for the development of antileptogenic and disease modifying drugs: A comparison of pharmacology of kindling and post status epilepticus models of temporal lobe epilepsy, *Epilepsy Research* 1999, 50, 105-23.
  - Devhare, L. D., Ghugare, A. P., & Hatwar, B. P. (2015). Method development for determination of water content from various materials by spectrophotometry and it's validation. *International journal of drug delivery*, 7(4), 233-240.
  - Devhare, L. D., & Kore, P. K. (2016). A recent review on bioavailability and solubility enhancement of poorly soluble drugs by physical and chemical modifications. *Research chronicle in health sciences*, 2(5), 299-308.
  - Tonde, T. U., Kasliwal, R. H., & Devhare, L. D. (2016). Quantitative Estimation of Bacoside A in Polyherbal Memory Enhancer Syrup for Memory Boosting Activity Using HPTLC Method. *Research Chronicle in Health Sciences*, 2(6), 315-320.
  - Ghugare, A. P., Devhare, L. D., & Hatwar, B. P. (2016) Development and validation of analytical methods for the simultaneous estimation of Nimorazole and Ofloxacin in tablet dosage form. 8(3), 96-98.
  - Salpe, H. G., Devhare, L. D., Ghugare, A. P., & Singh, N. (2016). Formulation and evaluation of hpmc coated diltiazem hcl tablet and its comparison with other marketed

- preparation. Research chronicle in health sciences. 3(1), 11-17
20. Makhani, A. A., & Devhare, L. D. (2017). Development and validation of vierordt's spectrophotometric method for simultaneous estimation of Drotaverine and Nimesulide combination. Research chronicle in health sciences, 3(2), 22-28.
  21. Makhani, A. A., & Devhare, L. D. (2017). Development and Validation of Analytical Methods for Drotaverine and Nimesulide Combination. Research Chronicle in Health Sciences, 3(3), 40-44.
  22. Katole, G., & Devhare, L. D. (2020). Recent insight into some emerging natural resources with remarkable hepato protective potentials. International journal of pharmaceutical science and research, 5(1), 41-47.
  23. Uplanchiwar, V. P., Raut, S. Y., & Devhare, L. D. (2021). Pharmacological assessment of antiulcer activity of gloriosa superba linn tubers in experimentally induced gastric ulcers. Journal of medical pharmaceutical and allied science, 10(3), 2852-2856.
  24. Devhare, L. D., & Gokhale, N. (2021). Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants. Journal of Advanced Scientific Research, 12(04), 175-179.
  25. Devhare, L. D., & Gokhale, N. (2022). Antioxidant and Antiulcer property of different solvent extracts of Cassia tora Linn. Research Journal of Pharmacy and Technology, 15(3), 1109-1113.
  26. Devhare, L. D., & Gokhale, N. (2023). In silico anti-ulcerative activity evaluation of some bioactive compound from Cassia tora and Butea monosperma through molecular docking approach. International journal of pharmaceutical sciences and research, 14(2), 1000-1008.
  27. Devhare, L. D., & Gokhale, N. (2023). A brief review on: phytochemical and antiulcer properties of plants (fabaceae family) used by tribal people of gadchiroli maharashtra. International journal of pharmaceutical sciences and research, 14(4), 1572-1593.
  28. Nikam N, R., Vaishnavi, A., & Devhare, L. D. (2023). Parenteral drug delivery approach: an overview. Journal of xidian university, 17(1), 386-400.
  29. Shende, S. M., Bhandare, P., & Devhare, L. D. (2023). In-vitro: micropropagation of mint and investigate the antibacterial activity of mint extract. Eur. Chem. Bull, 12(5), 780-784.
  30. Bodhankar, S. S., Devhare, L. D., Meshram, A. S., Moharkar, D. W., & Badwaik, C. B. (2023). Formulation and in vitro evaluation of dental gel containing ethanglic extract of Mimosa pudica. European Chemical Bulletin, 12(5), 1293-1299.
  31. Devhare, L. D., Bodhankar, S. S., Warambhe, P., Uppalwar, S. V., Uchibagle, S., & Shende, S. M. (2023). Important role of food and nutritional security during Covid-19: A survey. European Chemical Bulletin. 12(5), 1363-1374.
  32. Pathak, N. R., Devhare, L. D., Sawarkar, K. R., Dubey, M., Trivedi, V., Thakre, A. R., & Thakare, V. M. (2023). Aclinal reveiw on pharmacological evaluation of Thiazolidine and Isatin in the new millenium as magic moieties. European Chemical Bulletin. 12(5), 3410-3417.
  33. Singh, S., Minj, K. H., Devhare, L. D., Uppalwar, S. V., Anand, S., Suman, A., & Devhare, D. L. (2023). An update on morphology, mechanism,

- lethality, and management of dhatura poisoning. *European Chemical Bulletin*. 12(5), 3418-3426.
34. Suruse, P. B., Jadhav, B. A., Barde, L. G., Devhare, L. D., Singh, S., Minj, K. H., & Suman, A. (2023). Exploring the potential of *Aerva Lanata* extract in a herbal ointment for fungal infection treatment. *Journal of Survey in Fisheries Sciences*. 10(1), 1922-1932.
35. Shende, S. M., Meshram, B., Karemore, H., & Devhare, L. D. (2023). Development And Characterization of Glycerogelatin Suppositories For Enhanced Efficacy. *European Journal of Pharmaceutical and Medical Research*. 10(6), 522-528.
36. Thakare, V. M., Umare, S. A., & Devhare, L. D. (2023). Separation and purification of carboxymethyl cellulose from *Spinacia Oleracea* for use in pharmaceutical dosage form. *European Chemical Bulletin*. 12(5), 4062-4080.
37. Suruse, P. B., Deshmukh, A. P., Barde, L. G., Devhare, L. D., Maurya, V. K., Deva, V., & Priya, N. S. (2023). Rimegepant embedded fast dissolving films: A novel approach for enhanced migraine relief. *Journal of Survey in Fisheries Sciences*, 10(1) 2071-2084.
38. Prasad, M., Suman, A., Srivastava, S., Khosla, G., Deshmukh, A., Devhare, L. D., & Meshram, S. S. *Butea monosperma* stem bark extract partially reverses high fat diet-induced obesity in rats. *European Chemical Bulletin*. 12(5), 4267 – 4273.
39. Shukla, M., Tiwari, S. A., Desai, S. R., Kumbhar, S. T., Khan, M. S., Mavai, Y., & Devhare, L. D. (2023). Pharmacological Evaluation of *Gloriosa Superba* Linn Flower Extract For Antiulcer Activity. *Journal of Survey in Fisheries Sciences*. 10(2) 463-470.
40. Polireddy, P., Malviya, V., & Devhare, L. D. (2023). Assessment of Hepatoprotective Potential of *Ecbolium Linneanum* Extract on Experimental Animals. *Journal of Coastal Life Medicine*. 2(11) 884-890
41. Devhare, L. D., Hiradeve, S. M., & Bobade, T. (2017). *Method Development & Validation For Determination of Water Content*. LAP LAMBERT Academic Publishing.

**Table 1: Effect of ethanolic extract of leaves of *Nigella sativa* on MES induced convulsions in mice.**

Treatment	Dose	Onset of clonus convulsion (sec)	Duration of extensor convulsion (sec)
Control	2% gum acacia	26 ± 0.57	24 ± 0.57
Phenytoin	25mg/kg p.o.	6.53 ± 0.60	5.9 ± 0.60
EENS	400mg/kg p.o.	23.16 ± 0.60	23.16 ± 0.60
EENS	600mg/kg p.o.	17.33 ± 0.66**	13.33 ± 0.66**
EENS	800mg/kg p.o.	14.84 ± 0.60**	12.83 ± 0.60**


Values are mean ± SEM; n=6; One way analysis of variance (ANOVA) followed by Dunnett's, "t" test. Where, \*\*represents highly significant at p<0.01, EENS: ethanolic extract of leaves of *Nigella sativa* MES: Maximal electro shock.

**Table 2: Effect of EENS leaves on PTZ (60mg/kg) induced convulsion in mice**

Treatment	Dose	Onset of convulsion (sec)	Duration of convulsion (sec)
Control	2% gum acacia	670.5 ±10.135	39.66 ± 0.66
Diazepam	5mg/kg p.o.	908.83 ±15.39	6.83 ± 0.71
EENS	400mg/kg p.o.	724.5 ±15.23*	23 ± 0.96
EENS	600mg/kg p.o.	791.16 ±9.02**	19.33 ± 0.91**
EENS	800mg/kg p.o.	823.33 ±7.81**	15.33 ± 0.49**

Values are mean ± SEM; n=6; One way analysis of variance (ANOVA) followed by Dunnett's, "t" test. Where, \*\*represents highly significant at p<0.01, EENS: ethanolic extract of leaves of *Nigella sativa* MES: Maximal electro shock.



**Fig. 01 Percentage Convulsion Protection Activity of EECN Against PTZ Induced Convulsions In Mice**

A: 2% gum acacia p.o., B: Diazepam 5mg/kg p.o., C: EECN 400mg/kg p.o., D: EECN 600mg/kg p.o., E: EECN 800mg/kg p.o.